Search Results - "Riederer, Peter"

Monoamine oxidase-B inhibitors in the treatment of Parkinson’s disease: clinical–pharmacological aspects by Riederer, Peter, Müller, Thomas

“…This invited narrative review emphasizes the role of MAO-B inhibition in the drug portfolio for dopamine substitution in patients with Parkinson’s disease…”
Get full text

Modulation of monoamine oxidase (MAO) expression in neuropsychiatric disorders: genetic and environmental factors involved in type A MAO expression by Naoi, Makoto, Riederer, Peter, Maruyama, Wakako

“…Monoamine oxidase types A and B (MAO-A, MAO-B) regulate the levels of monoamine neurotransmitters in the brain, and their dysfunction may be involved in the…”
Get full text

The Nigral Coup in Parkinson's Disease by α-Synuclein and Its Associated Rebels by Sian-Hulsmann, Jeswinder, Riederer, Peter

“…The risk of Parkinson's disease increases with age. However, the etiology of the illness remains obscure. It appears highly likely that the neurodegenerative…”
Get full text

Botulinum toxin’s axonal transport from periphery to the spinal cord by Matak, Ivica, Riederer, Peter, Lacković, Zdravko

“…Occurrence of cleaved SNAP-25 in ipsilateral lumbal ventral horn following botulinum toxin A (30U/kg) subcutaneous injection into the rat hind paw. [Display…”
Get full text

Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson’s disease by Szökő, Éva, Tábi, Tamás, Riederer, Peter, Vécsei, László, Magyar, Kálmán

“…The era of MAO-B inhibitors dates back more than 50 years. It began with Kálmán Magyar’s outstanding discovery of the selective inhibitor, selegiline. This…”
Get full text

The relevance of iron in the pathogenesis of Parkinson’s disease by Sian‐Hülsmann, Jeswinder, Mandel, Silvia, Youdim, Moussa B. H., Riederer, Peter

“…J. Neurochem. (2011) 118, 939–957. Alterations of iron levels in the brain has been observed and documented in a number of neurodegenerative disorders…”
Get full text

New Aspects Regarding the Fluorescence Spectra of Melanin and Neuromelanin in Pigmented Human Tissue Concerning Hypoxia by Leupold, Dieter, Buder, Susanne, Pfeifer, Lutz, Szyc, Lukasz, Riederer, Peter, Strobel, Sabrina, Monoranu, Camelia-Maria

“…Melanin is a crucial pigment in melanomagenesis. Its fluorescence in human tissue is exceedingly weak but can be detected through advanced laser spectroscopy…”
Get full text

Perspective: Treatment for Disease Modification in Chronic Neurodegeneration by Müller, Thomas, Mueller, Bernhard Klaus, Riederer, Peter

“…Symptomatic treatments are available for Parkinson's disease and Alzheimer's disease. An unmet need is cure or disease modification. This review discusses…”
Get full text

TDM in psychiatry and neurology: A comprehensive summary of the consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology, update 2017; a tool for clinicians by Schoretsanitis, Georgios, Paulzen, Michael, Unterecker, Stefan, Schwarz, Markus, Conca, Andreas, Zernig, Gerald, Gründer, Gerhard, Haen, Ekkerhard, Baumann, Pierre, Bergemann, Niels, Clement, Hans Willi, Domschke, Katharina, Eckermann, Gabriel, Egberts, Karin, Gerlach, Manfred, Greiner, Christine, Havemann-Reinecke, Ursula, Hefner, Gudrun, Helmer, Renate, Janssen, Ger, Jaquenoud-Sirot, Eveline, Laux, Gerd, Messer, Thomas, Mössner, Rainald, Müller, Matthias J., Pfuhlmann, Bruno, Riederer, Peter, Saria, Alois, Schoppek, Bernd, Silva Gracia, Margarete, Stegmann, Benedikt, Steimer, Werner, Stingl, Julia C., Uhr, Manfred, Ulrich, Sven, Waschgler, Roland, Zurek, Gabriela, Hiemke, Christoph

“…Objectives: Therapeutic drug monitoring (TDM) combines the quantification of drug concentrations in blood, pharmacological interpretation and treatment…”
Get full text

Biological markers for anxiety disorders, OCD and PTSD - a consensus statement. Part I: Neuroimaging and genetics by Bandelow, Borwin, Baldwin, David, Abelli, Marianna, Altamura, Carlo, Dell'Osso, Bernardo, Domschke, Katharina, Fineberg, Naomi A., Grünblatt, Edna, Jarema, Marek, Maron, Eduard, Nutt, David, Pini, Stefano, Vaghi, Matilde M., Wichniak, Adam, Zai, Gwyneth, Riederer, Peter

“…Objectives: Biomarkers are defined as anatomical, biochemical or physiological traits that are specific to certain disorders or syndromes. The objective of…”
Get full text

Introduction to the special issue on monoamine oxidase A and B: eternally enigmatic isoenzymes by Shih, Jean Chen, Riederer, Peter, Maruyama, Wakako, Naoi, Makoto

Get full text

Safety of Cerebrolysin for Neurorecovery after Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of Twelve Randomized-Controlled Trials by Strilciuc, Stefan, Vécsei, László, Boering, Dana, Pražnikar, Aleš, Kaut, Oliver, Riederer, Peter, Battistin, Leontino

“…We performed a systematic search and meta-analysis of available literature to determine the safety profile of Cerebrolysin in acute ischemic stroke, filling…”
Get full text

Cerebral amyloid angiopathy in streptozotocin rat model of sporadic Alzheimer’s disease: a long-term follow up study by Salkovic-Petrisic, Melita, Osmanovic-Barilar, Jelena, Brückner, Martina K., Hoyer, Siegfried, Arendt, Thomas, Riederer, Peter

“…Cerebral amyloid angiopathy is manifested as accumulation of amyloid β (Aβ) peptide in the wall of meningeal and cerebral arteries, arterioles and capillaries…”
Get full text

Postencephalitic Parkinsonism: Unique Pathological and Clinical Features-Preliminary Data by Strobel, Sabrina, Sian-Hulsmann, Jeswinder, Tappe, Dennis, Jellinger, Kurt, Riederer, Peter, Monoranu, Camelia-Maria

“…Postencephalitic parkinsonism (PEP) is suggested to show a virus-induced pathology, which is different from classical idiopathic Parkinson's disease (PD) as…”
Get full text

Different methylation of the TNF-alpha promoter in cortex and substantia nigra: Implications for selective neuronal vulnerability by Pieper, Heike C, Evert, Bernd O, Kaut, Oliver, Riederer, Peter F, Waha, Andreas, Wüllner, Ullrich

“…Abstract Increasing evidence has linked inflammatory processes to neurodegenerative disorders, including Alzheimer's and Parkinson's disease (PD). Tumor…”
Get full text

From attention-deficit hyperactivity disorder to sporadic Alzheimer's disease-Wnt/mTOR pathways hypothesis by Grünblatt, Edna, Homolak, Jan, Babic Perhoc, Ana, Davor, Virag, Knezovic, Ana, Osmanovic Barilar, Jelena, Riederer, Peter, Walitza, Susanne, Tackenberg, Christian, Salkovic-Petrisic, Melita

“…Alzheimer's disease (AD) is the most common neurodegenerative disorder with the majority of patients classified as sporadic AD (sAD), in which etiopathogenesis…”
Get full text

Aldehyde dehydrogenase (ALDH) in Alzheimer’s and Parkinson’s disease by Grünblatt, Edna, Riederer, Peter

Get full text

Streptozotocin Impairs Proliferation and Differentiation of Adult Hippocampal Neural Stem Cells in Vitro -Correlation With Alterations in the Expression of Proteins Associated With the Insulin System by Sun, Ping, Ortega, Gabriela, Tan, Yan, Hua, Qian, Riederer, Peter F, Deckert, Jürgen, Schmitt-Böhrer, Angelika G

“…Rats intracerebroventricularily (icv) treated with streptozotocin (STZ), shown to generate an insulin resistant brain state, were used as an animal model for…”
Get full text

Chronic monoamine oxidase-B inhibitor treatment blocks monoamine oxidase-A enzyme activity by Bartl, Jasmin, Müller, Thomas, Grünblatt, Edna, Gerlach, Manfred, Riederer, Peter

“…Patients with Parkinson’s disease receive selective irreversible monoamine oxidase (MAO)-B inhibitors, but their effects on MAO-A activity are not known during…”
Get full text

Lewy Bodies: A Spectator or Salient Killer? by Sian-Hulsmann, Jeswinder, Monoranu, Camelia, Strobel, S, Riederer, Peter

“…Lewy bodies (LBs) are characteristic hallmarks of Parkinson's disease (PD). However, their role in the pathology of PD is not established yet. Are they primary…”
Get more information